Molecular Vision: Gushansky, Mol Vis 2025; 31:345-349. Table 1

Table 1. Baseline clinical characteristics among 40 central retinal vein occlusion patients.

Variable	Glycemic control		P value
Variable	Good (n=30)	Poor (n=10)	P value
Age (years)	78.0±8.0	72.4±8.2	0.032
Females (%/n)	53% (16)	50% (5)	0.855
HbA1c (mmol/mol)	37.3±2.9	58.0±14.7	<0.001
Smokers (%)*	26% (5 out of 19)	33% (2 out of 6)	0.739
Glaucoma (%/n)	23% (7)	30% (3)	0.673
Antihypertensives (%/n)	87% (26)	50% (5)	0.162
Statin (n/%)	83% (25)	60% (6)	0.274
ASA (%/n)	37% (11)	30% (3)	0.702
Chronic kidney disease (%/n)	10% (3)	0% (-)	0.560
Contralateral eye retinal laser (n/%)	0% (-)	10% (1)	0.250
Contralateral eye anti-VEGF (n/%)	0% (-)	10% (1)	0.250
CMT (µm)	469.6±284.2	490.9±261.0	0.434
BCVA (LogMAR)	0.78±0.86	1.20±0.87	0.409
Second-line intravitreal treatments at 1-year (%/n)
Aflibercept	10% (3)	10% (1)	0.543
Dexamethasone implant	3% (1)	-	0.559

Good glycemic control; mean HbA1c <42 mmol/mol. Poor glycemic control; mean HbA1c ≥42mmol/mol. Antihypertensives; blood pressure medication, ASA; acetylsalicylic acid treatment, BCVA; best-corrected visual acuity, CMT; central macular thickness (mean thickness in the central 1000- µ m diameter area), HbA1c; hemoglobin A1c, LogMAR; logarithm of the minimum angle of resolution, statin; HMG-CoA reductase inhibitor treatment. *Smoking status was confirmed for 25 patients. Bold=p<0.05.